Biblio

Author Title Type [ Year

]

Filters: Author is Liu, Kai-Yan [Clear All Filters]

2020

Zhang J-M, Xu Y, Gale RP, Wu L-X, Zhang J, Feng Y-H, Qin Y-Z, Jiang H, Jiang Q, Jiang B, et al. DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. Br J Haematol. 2020.

Zeng Q-Z, Zhang Y-Y, Wu Y-J, Zhang Z-Y, Zhang J-N, Fu H-X, Wang J-Z, Wang F-R, Yan C-H, Mo X-D, et al. Frequency, risk factors and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.

Han T-T, Zhang Y-N, Sun Y-Q, Kong J, Wang F-R, Wang Z-D, Cheng Y-F, Yan C-H, Wang Y, Xu L-P, et al. Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graft-versus-host disease. Transpl Infect Dis. 2020:e13544.

Xu Z-L, Cheng Y-F, Zhang Y-Y, Mo X-D, Han T-T, Wang F-R, Yan C-H, Sun Y-Q, Chen Y-H, Tang F-F, et al. The incidence, clinical outcome and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clin Transplant. 2020:e14160.

Wang Z-L, Liu Y, Zhou Y-L, Li J-L, Sun Q-Y, Wu L-X, Wen L, Lai Y-Y, Liu Y-R, Chang Y-J, et al. Osteoclast stimulatory transmembrane protein (OC-STAMP) is a promising molecular prognostic indicator for multiple myeloma. Eur J Haematol. 2020.

Chen Q, Zhao X, Fu H-X, Chen Y-H, Zhang Y-Y, Wang J-Z, Wang Y, Wang F-R, Mo X-D, Han W, et al. Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2020.

Bai L, Cheng Y-F, Lu A-D, Suo P, Wang Y, Zuo Y-X, Yan C-H, Wu J, Jia Y-P, Sun Y-Q, et al. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia. Leuk Res. 2020;91:106333.

Liu S-N, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, et al. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute GVHD: updated experienced from a large-scale study. Am J Hematol. 2020.

Chang Y-J, Xu L-P, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, Yan C-H, et al. Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody. Bone Marrow Transplant. 2020.

2019

Ma R, Huang X-J, Xu L-P, Liu K-Y, Zhang X-H, Yan C-H, Han W, Wang F-R, Chen Y-H, Chen H, et al. Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Biol Blood Marrow Transplant. 2019.

Mo X-D, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, et al. Corrigendum to 'Interferon α: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation' [Biology of Blood and Marrow Transplantation 21/11 (2015) 19. Biol Blood Marrow Transplant. 2019.

Mo X-D, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, et al. Corrigendum to 'Interferon-α is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study' [Biology of Blood and Marrow Transplantation 23/8 (. Biol Blood Marrow Transplant. 2019.

Zhao X-Y, Yu X-X, Xu Z-L, Cao X-H, Huo M-R, Zhao X-S, Chang Y-J, Wang Y, Zhang X-H, Xu L-P, et al. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019;3(24):4312-4325.

Zhao X-Y, Pei X-Y, Chang Y-J, Yu X-X, Xu L-P, Wang Y, Zhang X-H, Liu K-Y, Huang X-J. First-line therapy with donor-derived HCMV-specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation. Clin Infect Dis. 2019.

Zhang Y-Y, Mo X-D, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, et al. FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients. Bone Marrow Transplant. 2019.

Wang X-L, Han W, Zhao P, Liu X, Wang J-Z, Wang F-R, Yan C-H, Zhang Y-Y, Mo X-D, Wang Y, et al. Incidence, Risk Factors, Outcomes and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019.

Wang X-Y, Fan Q-Z, Xu L-P, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, et al. The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. Cytometry B Clin Cytom. 2019.

Qin Y-Z, Wang Y, Xu L-P, Zhang X-H, Zhao X-S, Liu K-Y, Huang X-J. Subgroup Analysis Can Optimize the Relapse Prediction Cutoff Value for WT1 Expression Following Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia. J Mol Diagn. 2019.

Xue Y-J, Suo P, Huang X-J, Lu A-D, Wang Y, Zuo Y-X, Yan C-H, Wu J, Kong J, Zhang X-H, et al. Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukae. Br J Haematol. 2019.

2018

Xue Y-J, Cheng Y-F, Lu A-D, Wang Y, Zuo Y-X, Yan C-H, Wu J, Sun Y-Q, Suo P, Chen Y-H, et al. Allogeneic hematopoietic stem cell transplantation, especially haploidentical HSCT, may improve long-term survival for high-risk pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era. Biol Blood Marrow Transplant. 2018.

Chang Y-J, Xu L-P, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, Yan C-H, et al. Effects of low-dose glucocorticoid prophylaxis on chronic GVHD and GVHD-free, relapse-free survival after haploidentical transplantation: long-term follow-up of a controlled, randomized open-label trial. Biol Blood Marrow Transplant. 2018.

Yan C-H, Wang Y, Mo X-D, Sun Y-Q, Wang F-R, Fu H-X, Chen Y, Han T-T, Kong J, Cheng Y-F, et al. Incidence, Risk Factors, Microbiology and Outcomes of Pre-engraftment Bloodstream Infection After Haploidentical Hematopoietic Stem Cell Transplantation and Comparison With HLA-identical Sibling Transplantation. Clin Infect Dis. 2018;67(suppl_2):S162-S173.

Huo M-R, Xu Y-J, Zhai S-Z, Lv M, Wang Y, Cao L-Q, Xu L-P, Zhang X-H, Chen H, Chen Y-H, et al. Prevalence and risk factors of antibodies to human leukocyte antigens in haploidentical stem cell transplantation candidates: A multi-center study. Hum Immunol. 2018.

2016

Tang F-F, Huang X-J, Zhang X-H, Chen H, Chen Y-H, Han W, Chen Y, Wang F-R, Wang Y, Wang J-Z, et al. Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia. Leuk Res. 2016;47:8-15.

Xu L-P, Xu Z-L, Zhang X-H, Chen H, Chen Y-H, Han W, Chen Y, Wang F-R, Wang J-Z, Wang Y, et al. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia. Biol Blood Marrow Transplant. 2016.

Pages